RIPerC: Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles
RIPC: Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles
Study summary
At present, there are 290 million cardiovascular patients in China, including 11 million patients with coronary heart disease. Remote ischemic preconditioning(RIPC) may play an effective endogenous cardiac protection.This study will explore whether long-term use of RIPC in patients with AMI after PCI and non interventional therapy can reduce the incidence of major adverse cardiovascular cerebrovascular events(MACCE) and improve clinical outcomes and long-term prognosis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with acute myocardial infarction were diagnosed in accordance with the criteria of the "Global Unified Definition of Fourth Myocardial Infarction"
Exclusion Criteria:
* The patients could not tolerate RIPC or RIPerC
* Aortic dissection, coronary artery aneurysm, coronary artery fistula and other systemic organic diseases
* The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively
* severe liver dysfunction (bilirubin \> 20 mmol / L, prothrombin time \> 2.0 ratio)
* Severe renal insufficiency (GFR \< 30 ml / min / 1.73 m2);
* patients taking nicorandil and other drugs affecting microcirculation
* pregnant
Primary outcome measure(s)
Rate of MACCEs — 12 months after discharge MACCE(include Cardiovascular death, non-fatal acute myocardial infarction, revascularization, stroke, admission due to heart failure )
Trial sites (1)
Facility
City
Region
Status
Fuwai Central China Cardiovascular Hospital
Zhengzhou
Henan
Recruiting
More Henan Institute of Cardiovascular Epidemiology trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.